White Square Chemical Release: Novus Permanent Denture Liner Builds Global Distribution Network With European Deal
WILMINGTON, Delaware, January 26, 2016 /PRNewswire/ --
Owner of the Novus™ brand, White Square Chemical, Inc. builds momentum in key markets of Germany, Austria, Switzerland, Belgium and the Netherlands
White Square Chemical (WSQ or the Company), a specialized materials technology company whose primary business is the manufacture and commercial exploitation of PNF™ (polyphosphazene technology), a specialty polymer, has today confirmed that it has signed an exclusive distribution agreement with Novus BV for its lead product, Novus® a PNF™ based denture liner, covering the core European markets of the Netherlands, Germany, Austria, Switzerland, and Belgium.
Novus® http://www.novusliner.com is a long-standing and proven FDA-approved denture liner that WSQ intends to commercialize through a series of investments and partnerships.
Commenting on the European expansion, WSQ CEO Nick Hawkins said: "Novus® is a high-potential money-saving denture liner, with significant practitioner and patient benefits, which we know will be very well received in Europe. This new agreement will raise the profile of Novus® in Europe among these target audiences. It is a further step by WSQ to build momentum for a product that had not performed to its potential for some years. All in WSQ are delighted to have this chance to work with Novus BV for the development of the Novus® brand outside the United States."
Novus BV CEO Wilfred van Til added that: "Novus BV is already collaborating with a number of prosthodontist organisations in the Netherlands and the initial reactions have confirmed the view that Novus® is a revolutionary product."
Novus BV has launched social media platforms at http://www.novusliner.nl and http://www.facebook.com/novusbv .
The Novus® advantage - Comfort and Financial
In the United States over 6.5 million new denture arches are fitted annually. The corresponding estimated figure for European countries is approximately 5.0 million.
WSQ is focused on promoting Novus® as a primary health care tool to address an historic issue with denture discomfort by providing an effective, long lasting cushion between the traditional hard acrylic material from which the majority of dentures are manufactured and human soft tissue and the alveolar bone. In addition, Novus® has a proven ability to reduce the incidence of bad breath resulting from bacteria build-up.
Background - Chemistry and History
Novus™ is a PNF™ based denture liner. PNF™ is made from dichloropolymer ("DCP") and is an inorganic polyphosphazene material. The material was manufactured and sold in the 1980s and 1990s. PNF™ based products were originally developed and manufactured on a commercial scale by Firestone Corporation with US Department of Defense funding. Novus® was developed with a National Institute of Health grant and funding. Hygenic Corporation first commercially introduced the product into the international dental market in the late 1980s.
Since its formation in 2012, WSQ has been successfully developing a proprietary commercial manufacturing process for the production of DCP and PNF™. The existing manufacturing process is used today to provide large-scale production at WSQ's plant in Woburn, MA for the purposes of manufacturing Novus™.
About WSQ
WSQ's goal is to monetize its technology business by creating a continuous revenue stream based solely on DCP and PNF™ based products. Once an application is commercialized, WSQ http://www.wsqchem.com will form partnerships with strategic companies who specialize in the sector for which the PNF™ application is created. The Company has identified, and will bring to market during the course of 2016, other PNF™ based applications that were previously commercialized and have near-term cash generation profiles. In all, there are some 700-patented or identified applications for PNF™, which are stranded because of a lack of commercial scale manufacturing. These applications extend into the world of aerospace/defense, oil and gas, energy (lithium ion batteries) and biotech. WSQ is based in Wilmington DE and is managed by an experienced management team.
For further information please contact:
Nick Hawkins, CEO & Board Director, Nhawkins@wsqchem.com,
Adam A. Blanco, CFO & Board Director, ABlanco@wsqchem.com,
Novus BV (the Netherlands) info@novusliner.nl
SOURCE White Square Chemical
Owner of the Novus™ brand, White Square Chemical, Inc. builds momentum in key markets of Germany, Austria, Switzerland, Belgium and the Netherlands
White Square Chemical (WSQ or the Company), a specialized materials technology company whose primary business is the manufacture and commercial exploitation of PNF™ (polyphosphazene technology), a specialty polymer, has today confirmed that it has signed an exclusive distribution agreement with Novus BV for its lead product, Novus® a PNF™ based denture liner, covering the core European markets of the Netherlands, Germany, Austria, Switzerland, and Belgium.
Novus® http://www.novusliner.com is a long-standing and proven FDA-approved denture liner that WSQ intends to commercialize through a series of investments and partnerships.
Commenting on the European expansion, WSQ CEO Nick Hawkins said: "Novus® is a high-potential money-saving denture liner, with significant practitioner and patient benefits, which we know will be very well received in Europe. This new agreement will raise the profile of Novus® in Europe among these target audiences. It is a further step by WSQ to build momentum for a product that had not performed to its potential for some years. All in WSQ are delighted to have this chance to work with Novus BV for the development of the Novus® brand outside the United States."
Novus BV CEO Wilfred van Til added that: "Novus BV is already collaborating with a number of prosthodontist organisations in the Netherlands and the initial reactions have confirmed the view that Novus® is a revolutionary product."
Novus BV has launched social media platforms at http://www.novusliner.nl and http://www.facebook.com/novusbv .
The Novus® advantage - Comfort and Financial
In the United States over 6.5 million new denture arches are fitted annually. The corresponding estimated figure for European countries is approximately 5.0 million.
WSQ is focused on promoting Novus® as a primary health care tool to address an historic issue with denture discomfort by providing an effective, long lasting cushion between the traditional hard acrylic material from which the majority of dentures are manufactured and human soft tissue and the alveolar bone. In addition, Novus® has a proven ability to reduce the incidence of bad breath resulting from bacteria build-up.
Background - Chemistry and History
Novus™ is a PNF™ based denture liner. PNF™ is made from dichloropolymer ("DCP") and is an inorganic polyphosphazene material. The material was manufactured and sold in the 1980s and 1990s. PNF™ based products were originally developed and manufactured on a commercial scale by Firestone Corporation with US Department of Defense funding. Novus® was developed with a National Institute of Health grant and funding. Hygenic Corporation first commercially introduced the product into the international dental market in the late 1980s.
Since its formation in 2012, WSQ has been successfully developing a proprietary commercial manufacturing process for the production of DCP and PNF™. The existing manufacturing process is used today to provide large-scale production at WSQ's plant in Woburn, MA for the purposes of manufacturing Novus™.
About WSQ
WSQ's goal is to monetize its technology business by creating a continuous revenue stream based solely on DCP and PNF™ based products. Once an application is commercialized, WSQ http://www.wsqchem.com will form partnerships with strategic companies who specialize in the sector for which the PNF™ application is created. The Company has identified, and will bring to market during the course of 2016, other PNF™ based applications that were previously commercialized and have near-term cash generation profiles. In all, there are some 700-patented or identified applications for PNF™, which are stranded because of a lack of commercial scale manufacturing. These applications extend into the world of aerospace/defense, oil and gas, energy (lithium ion batteries) and biotech. WSQ is based in Wilmington DE and is managed by an experienced management team.
For further information please contact:
Nick Hawkins, CEO & Board Director, Nhawkins@wsqchem.com,
Adam A. Blanco, CFO & Board Director, ABlanco@wsqchem.com,
Novus BV (the Netherlands) info@novusliner.nl
SOURCE White Square Chemical